Bupivacaine liposome for Cardiac Conditions (CohortI-II Trial)

"This research requires 30 volunteer participants aged between two and seventeen who have a cardiac disorder. In addition, all entrants must meet the following criteria: All elective pediatric surgical patients ranging from two to seventeen years of age inclusive."

"The qualifications for inclusion in this study demand that participants are between the age of 2 and 17. Currently, there exists 23 clinical trials tailored to minors and 170 studies for those over 65 years old."

"Affirmative. Clinicaltrials.gov logs indicate that this medical research project, which was initially posted on July 15th 2021 is actively seeking patients to join their study. 30 individuals need to be enrolled from 1 clinical site."

"Bupivacaine liposome is an applicable treatment for permphigus, acute nonspecific tenosynovitis and general anesthesia."

"Due to the limited data collected in this Phase 1 trial, our team at Power gave Bupivacaine liposome a score of one for safety standards."

"Currently, research is being conducted on Bupivacaine liposome in 109 trials with 18 of them having reached Phase 3. Of those studies taking place in the USA, the majority are situated around Philadelphia; nonetheless, there are a total of 144 sites offering this treatment."

"Affirmative, the information on clinicaltrials.gov suggests that this trial is actively enrolling patients. It was initially published on July 15th 2021 and has since been updated as recently as April 4th 2022. 30 individuals are in need of recruitment at 1 medical centre."